Mood Swings in Male-to-Female Hormone Therapy
Current evidence indicates that trans women undergoing feminizing hormone therapy (estrogen and anti-androgens) do experience mood swings, particularly during the first 3-6 months of treatment, but these changes are generally associated with overall improvements in mental health rather than adverse psychiatric outcomes. 1
Expected Emotional Changes During Early Treatment
The Endocrine Society Clinical Practice Guidelines document the timeline of feminizing effects in male-to-female transition 2. While mood swings are not explicitly listed in the standardized physical effects table, prospective research directly addressing subjective symptoms provides clear evidence:
- Mood swings and emotional instability increase persistently during the first 12 months of feminizing hormone therapy 1
- These changes typically begin within the first 3-6 months of treatment initiation
- The pattern represents a shift toward affect variability profiles more consistent with cisgender women 3
The Paradox: Mood Changes vs. Mental Health Improvement
Critically, while mood swings do occur, they should not be conflated with psychiatric deterioration. The most recent systematic review evidence demonstrates:
- No evidence that gender-affirming hormone therapy has adverse mental health outcomes 4
- Depression decreases by approximately 20% after 1 year of treatment in both trans women and trans men 4
- Quality of life improves by 16% in trans women after 1 year 4
- Overall psychoneurotic distress decreases most prominently after hormone therapy initiation 5
Clinical Context and Counseling Points
What to Tell Patients:
Trans women should expect increased emotional variability, including:
- Mood swings (persistent throughout first year) 1
- Emotional instability (persistent throughout first year) 1
- Breast tenderness (persistent) 1
- Hot flashes and night sweats (persistent) 1
Important Distinction:
The 2025 study on affect variability clarifies that variability in low mood increased after 3 and 12 months in the feminizing hormone group 3. This represents fluctuation patterns rather than sustained negative mood states. The increased variability reflects a normalization toward cisgender female patterns of emotional experience.
Monitoring Recommendations:
While the 2009 Endocrine Society guidelines mention monitoring for "adverse psychological changes" in trans men on testosterone 2, they do not specifically flag mood swings as a concerning adverse event requiring intervention in trans women. The guidelines emphasize:
- Regular psychological monitoring during endocrine transition
- Pretreatment counseling about all expected effects
- Recognition that these changes occur within a context of overall mental health improvement
Critical Caveat About Testosterone Studies
Disregard evidence from 6 regarding testosterone and depression in cisgender men—this is not applicable to trans women receiving feminizing therapy. Trans women receive estrogen and anti-androgens, not testosterone, making this study irrelevant to the question at hand.
Bottom Line for Clinical Practice
Counsel trans women that mood swings are a common, expected effect of feminizing hormone therapy that typically emerges in the first 3-6 months and may persist throughout the first year. 1 However, reassure them that:
- This does not represent psychiatric deterioration
- Overall mental health typically improves significantly
- These changes reflect a shift toward typical female hormonal patterns
- The benefits in terms of quality of life and reduced gender dysphoria substantially outweigh these transient emotional adjustments 4
The occurrence of mood swings should not be considered a reason to discontinue or avoid hormone therapy, as the overall trajectory is toward improved psychological well-being.